Novo Nordisk initiates trial with obesity-treating tablet

On Wednesday afternoon, Novo Nordisk announced that the molecule semaglutide will soon be tested in tablet form in a phase IIIa trial to treat obesity.

Photo: Novo Nordisk / PR

Novo Nordisk plans to initiate a new phase IIIa trial program against obesity with the firm's molecule semaglutide, according to a press release on Wednesday afternoon.

Notably, the trial revolves around oral semaglutide.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs